Stage 2: Antidepressants II — Atypical & Novel
Concept 1 of 8
R2.1

Bupropion (Wellbutrin)

NDRI — energy, focus, no sexual dysfunction, no weight gain.

Bupropion: weak NET + DAT reuptake inhibition with no SERT activity. The "non-serotonergic" antidepressant — different side effect profile reflects different synaptic target.

Bupropion — Wellbutrin — is the non-serotonergic antidepressant. Where every other first-line antidepressant works on serotonin in some way, bupropion does not. It blocks the dopamine transporter and the norepinephrine transporter — weakly, but enough — and has no meaningful SERT activity. That single mechanistic fact produces an entirely different side effect profile, and it is why bupropion has the role it does in modern prescribing.

Drug card
Class
Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)
Mechanism
Weak NET + DAT reuptake inhibition; no significant SERT activity. Also nicotinic antagonist.
Typical dose
Bupropion XL 150-450 mg/day; SR 100-200 mg BID; IR 75-100 mg TID
Half-life
~21 hours
FDA indications
MDD, seasonal affective disorder, smoking cessation (as Zyban)
Key adverse effects
Activation/insomnia, dry mouth, headache, weight loss (not gain), no sexual dysfunction, lowered seizure threshold (dose-dependent — avoid in bulimia/anorexia/seizure history)

Black box: Suicidal thinking/behavior in pediatric and young adult patients

First-line consideration when SSRI side effects (sexual dysfunction, weight gain, fatigue) are problematic. Often added to SSRI to augment partial response and counteract sexual side effects. Avoid in eating disorders and seizure history.

The advantages are clinical and specific. No sexual dysfunction — bupropion is essentially neutral on libido and orgasm where SSRIs cause 30 to 70 percent rates of impairment. No weight gain — most patients lose modest weight rather than gaining. No sedation — bupropion is activating, sometimes too activating, but not the heavy fatigue some SSRIs produce. For the patient bothered by SSRI sexual side effects, by weight creep, by the flat affect some patients describe on serotonergic agents, bupropion offers a different profile altogether.

The bupropion advantage: no sexual dysfunction (vs 30-70% on SSRIs), no weight gain (often weight loss), activating rather than sedating.

Bupropion is also the antidepressant you reach for as an SSRI augmenter. When a patient is doing partially well on sertraline but reports lost libido and fatigue, adding bupropion frequently helps both problems while preserving the SSRI's anxiolytic benefit. It's one of the most evidence-supported combination strategies in psychiatry.

Mechanism in practice

Bupropion is the antidepressant defined by what it is not — no serotonergic activity — and what it is: a norepinephrine-dopamine reuptake inhibitor with a distinctive activating, weight- and sexually-neutral profile.

Mechanism
Norepinephrine and dopamine reuptake inhibition (NDRI)
Effect
Raised noradrenergic and dopaminergic tone; activation, improved energy and focus
Clinical applications
Useful when fatigue, hypersomnia, and poor concentration dominate; the activating profile suits the anergic depression.
Mechanism
Absence of serotonergic activity
Effect
No sexual dysfunction, no weight gain, no serotonergic GI effects
Clinical applications
First choice when sexual side effects of SSRIs are a problem — used as monotherapy or to augment/replace an SSRI for that reason.
Mechanism
Dopaminergic effect in reward circuitry
Effect
Reduced nicotine craving and withdrawal
Clinical applications
FDA-approved for smoking cessation (Zyban); pulls double duty in the depressed smoker.
Mechanism
Dose-dependent lowering of the seizure threshold
Effect
Seizure risk, especially in bulimia, with alcohol withdrawal, or at high doses
Clinical applications
Contraindicated in seizure disorders and eating disorders; use XL formulation and respect dose ceilings to minimize risk.

Mechanism note: Bupropion's clinical niche is the mirror image of the SSRI: activating rather than calming, weight- and sexually-neutral rather than not. The seizure-threshold caveat defines who cannot take it.

And bupropion has a second life as a smoking cessation agent, marketed as Zyban for that indication. The mechanism is in part NDRI and in part nicotinic acetylcholine receptor antagonism. The dose ranges are similar to the antidepressant doses. For a depressed patient who also smokes, bupropion is the rare drug that targets both problems with one prescription.

The cost is the seizure threshold. Bupropion lowers seizure threshold in a dose-dependent way. The immediate-release formulation has the highest seizure rate; sustained release lowers it; XL lowers it further. At normal doses with no risk factors, the absolute risk is low — comparable to other antidepressants. The risk rises substantially in specific situations, and those situations define the contraindications: seizure history, bulimia or anorexia (where electrolyte disturbances amplify the risk), and abrupt sedative-hypnotic withdrawal. Avoid bupropion in those patients.

Dose-dependent seizure risk. Contraindications: seizure history, bulimia/anorexia, abrupt sedative-hypnotic withdrawal. XL formulation has lowest seizure rates.

Other side effects are typically modest. Insomnia is the most common — especially if the second dose is given too late in the day. Dry mouth, headache, tremor, and dose-dependent anxiety or jitteriness occur. Activation can be a feature (good for the patient with anergic depression) or a problem (bad for the patient with prominent anxiety). Match the drug to the picture.

Dosing: XL is the standard form. Start 150 milligrams once daily for a week, increase to 300 milligrams daily. Some patients tolerate and benefit from 450 milligrams XL. The SR formulation is dosed BID with the same total daily dose. Avoid IR when long-acting is available — fewer peaks, lower seizure rates, better adherence.

Prescribing reality
Cost
Generic XL: ~$10-30/month. Brand Wellbutrin XL/Forfivo ~$400+/month.
Generic status
Generic XL since 2006. Some generic XL formulations have had bioequivalence concerns historically; modern generics generally reliable.
Formulary typical
Tier 1-2 generic. Brand requires PA.
Access friction
Easy. Zyban (for smoking cessation) is same molecule with different brand — sometimes covered separately.

Prescriber tip: Generic XL is reliable. Avoid IR formulation when long-acting available (seizure risk). Some patients swear by brand; mostly placebo-of-brand effect.

Bupropion is the antidepressant for the patient who needs energy, doesn't need anxiolysis, can't tolerate sexual side effects or weight gain, and doesn't have an eating disorder or seizure history. For the right patient, it's not a second choice — it's the right first choice.

The anchor

Bupropion is the non-serotonergic antidepressant — NDRI mechanism produces energy/focus/smoking-cessation benefits without sexual dysfunction or weight gain. Seizure risk constrains dose and contraindicates in eating disorders.

Prove it

A patient on sertraline 100 mg has good mood improvement but reports sexual dysfunction and fatigue. What augmentation strategy addresses both?

This connects to

Locked concepts unlock as you reach them on the path.

Back